Adaptive Biotechnologies (ADPT) Cash & Equivalents (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash & Equivalents across 9 years of filings, most recently posting $169.9 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 293.56% year-over-year to $169.9 million; the TTM figure through Jun 2026 stood at $169.9 million (up 293.56% YoY), while the FY2025 annual figure was $70.5 million, up 47.11% from the prior year.
• Cash & Equivalents came in at $169.9 million for Q2 2026 at Adaptive Biotechnologies, up from $77.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $217.6 million in Q3 2022 to a low of $38.1 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $85.6 million, with a median of $73.8 million recorded in 2022.
• Year-over-year, Cash & Equivalents sank 59.22% in 2023 and soared 293.56% in 2026.
• Over 5 years, Cash & Equivalents stood at $90.0 million in 2022, then decreased by 27.73% to $65.1 million in 2023, then slipped by 26.35% to $47.9 million in 2024, then jumped by 47.11% to $70.5 million in 2025, then surged by 140.97% to $169.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $169.9 million in Q2 2026, $77.6 million in Q1 2026, and $70.5 million in Q4 2025.